About Henry Schein (NASDAQ:HSIC)
Henry Schein, Inc. is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The technology and value-added services segment provides software, technology and other value-added services to healthcare practitioners. Its technology group offerings include practice management software systems for dental and medical practitioners and animal health clinics. The Company provides its services to dental practitioners and laboratories, animal health clinics and physician practices, as well as government and institutional healthcare clinics.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment Wholesale
- Sub-Industry: Health Care Distributors
- Symbol: NASDAQ:HSIC
- CUSIP: 80640710
- Web: www.henryschein.com
- Market Cap: $13.36521 billion
- Outstanding Shares: 158,111,000
- 50 Day Moving Avg: $82.35
- 200 Day Moving Avg: $87.30
- 52 Week Range: $73.11 - $93.50
Sales & Book Value:
- Trailing P/E Ratio: 24.21
- Foreward P/E Ratio: 20.66
- P/E Growth: 2.35
- Annual Revenue: $11.97 billion
- Price / Sales: 1.09
- Book Value: $18.48 per share
- Price / Book: 4.48
- EBITDA: $1.02 billion
- Net Margins: 4.59%
- Return on Equity: 19.91%
- Return on Assets: 8.34%
- Debt-to-Equity Ratio: 0.28%
- Current Ratio: 1.55%
- Quick Ratio: 0.85%
- Average Volume: 921,895 shs.
- Beta: 1.09
- Short Ratio: 5.11
Frequently Asked Questions for Henry Schein (NASDAQ:HSIC)
What is Henry Schein's stock symbol?
Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."
When did Henry Schein's stock split? How did Henry Schein's stock split work?
Henry Schein's stock split on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were issued to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.
How will Henry Schein's stock buyback program work?
Henry Schein declared that its Board of Directors has authorized a share buyback program on Tuesday, September 19th 2017, which authorizes the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 6.3% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's management believes its shares are undervalued.
How were Henry Schein's earnings last quarter?
Henry Schein, Inc. (NASDAQ:HSIC) issued its quarterly earnings data on Tuesday, August, 8th. The company reported $0.88 earnings per share for the quarter, beating analysts' consensus estimates of $0.87 by $0.01. The company had revenue of $3.06 billion for the quarter, compared to analyst estimates of $3.05 billion. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The firm's revenue for the quarter was up 6.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.82 earnings per share. View Henry Schein's Earnings History.
When will Henry Schein make its next earnings announcement?
What guidance has Henry Schein issued on next quarter's earnings?
Henry Schein updated its FY17 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of $7.17-7.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.29.
Where is Henry Schein's stock going? Where will Henry Schein's stock price be in 2017?
15 analysts have issued 12-month target prices for Henry Schein's stock. Their forecasts range from $81.50 to $109.00. On average, they expect Henry Schein's stock price to reach $92.89 in the next year. View Analyst Ratings for Henry Schein.
What are analysts saying about Henry Schein stock?
Here are some recent quotes from research analysts about Henry Schein stock:
- 1. According to Zacks Investment Research, "Henry Schein exited second-quarter 2017 on a solid note with earnings and sales beating the Zacks Consensus Estimate. Apart from balanced growth across all its operating segments, Henry Schein's share gains in both the U.S. and overseas markets raise optimism. We are also positive about the company opening a National Distribution Service Center to strengthen its presence in central Ohio. On the flip side, over the last three months, the company has underperformed the broader industry. Also, despite the better-than-expected earnings, we are disappointed with the company’s unchanged EPS guidance for 2017. Meanwhile, Henry Schein’s venture in digital dentistry through DENTSPLY SIRONA deal may intensify its already weak operating margin scenario on escalating education and training expenses. Also, foreign currency fluctuations continued to mar the company’s financials." (8/9/2017)
- 2. Evercore ISI analysts commented, "HSIC continues to deliver consistent HSD to LDD EPS growth despite an operating environment that has been somewhat mixed, albeit North American Dental continues to show signs of recovery. With the acquisition engine still churning and an elevated level of buybacks, management has been able to deliver the type of TSR expected and thus the valuation remains notably elevated on an absolute basis (less so on a relative basis). While we also value consistency and predictability, we acknowledge we missed the November entry point (fears of US slowdown) and thus at current levels see risk / reward as more fully balanced (particularly with extra week headwind in 2017 + unfavorable Fx environment). Given this dynamic we reiterate our Hold rating and argue shares are now accurately pricing in the current operating environment. Thus we await another period of uncertainty prior to revisiting our long-term constructive view on shares." (2/21/2017)
Are investors shorting Henry Schein?
Henry Schein saw a increase in short interest in the month of September. As of September 29th, there was short interest totalling 8,187,143 shares, an increase of 47.2% from the September 15th total of 5,562,584 shares. Based on an average daily volume of 1,754,214 shares, the days-to-cover ratio is presently 4.7 days. Currently, 5.3% of the shares of the stock are sold short.
Who are some of Henry Schein's key competitors?
Some companies that are related to Henry Schein include Essilor International SA (ESLOY), Zimmer Biomet Holdings (ZBH), Cerner Corporation (CERN), Incyte Corporation (INCY), C.R. Bard (BCR), Edwards Lifesciences Corporation (EW), Quintiles Transitional Holdings (Q), Cardinal Health (CAH), Mylan N.V. (MYL), Lonza Group Ag (LZAGY), AmerisourceBergen Corporation (Holding Co) (ABC), Smith & Nephew SNATS (SNN), Centene Corporation (CNC), Align Technology (ALGN), Eisai Co., Ltd (ESALY), Laboratory Corporation of America Holdings (LH), BioMarin Pharmaceutical (BMRN) and Teva Pharmaceutical Industries Limited (TEVA).
Who are Henry Schein's key executives?
Henry Schein's management team includes the folowing people:
- Stanley M. Bergman, Chairman of the Board, Chief Executive Officer
- James P. Breslawski CPA, President, Director; Chief Executive Officer of Henry Schein Global Dental Group
- Steven Paladino CPA, Chief Financial Officer, Executive Vice President, Director
- Peter McCarthy, President of Global Animal Health Group
- David C. McKinley, President of Corporate Commercial Development Group, Chief Commercial Officer
- Bob Minowitz, President, International Dental Group, EMEA Region
- Bridget A. Ross, President of Global Medical Group
- Gerald A. Benjamin, Chief Administrative Officer, Executive Vice President, Director
- Mark E. Mlotek, Chief Strategic Officer, Executive Vice President, Director
- Karen N. Prange, Executive Vice President; Chief Executive Officer of Global Animal Health, Medical and Dental Surgical Group
Who owns Henry Schein stock?
Henry Schein's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Swedbank (1.49%), Fisher Asset Management LLC (0.53%), PGGM Investments (0.23%), Tesco Pension Investment Ltd (0.19%), Mountain Pacific Investment Advisers Inc. ID (0.17%) and Nationwide Fund Advisors (0.16%). Company insiders that own Henry Schein stock include Barry J Alperin, David Mckinley, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lonnie Shoff, Lorelei Mcglynn, Louis W Sullivan, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Norman S Matthews, Paul Brons, Paul Rose, Peter M Mccarthy, Philip A Laskawy, Robert Minowitz, Stanley Komaroff, Stanley M Bergman and Steven Paladino. View Institutional Ownership Trends for Henry Schein.
Who bought Henry Schein stock? Who is buying Henry Schein stock?
Henry Schein's stock was bought by a variety of institutional investors in the last quarter, including Swedbank, Fisher Asset Management LLC, APG Asset Management N.V., PGGM Investments, Nationwide Fund Advisors, Mountain Pacific Investment Advisers Inc. ID, Shell Asset Management Co. and Tesco Pension Investment Ltd. View Insider Buying and Selling for Henry Schein.
How do I buy Henry Schein stock?
Shares of Henry Schein can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Henry Schein's stock price today?
MarketBeat Community Rating for Henry Schein (NASDAQ HSIC)MarketBeat's community ratings are surveys of what our community members think about Henry Schein and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Henry Schein stock can currently be purchased for approximately $82.85.
Consensus Ratings for Henry Schein (NASDAQ:HSIC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||10 Hold Ratings, 5 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.33)|
|Consensus Price Target: ||$92.89 (12.12% upside)|Consensus Price Target History for Henry Schein (NASDAQ:HSIC)
Analysts' Ratings History for Henry Schein (NASDAQ:HSIC)
(Data available from 10/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/20/2017||Jefferies Group LLC||Reiterated Rating||Hold||$89.00||N/A|
|10/19/2017||Robert W. Baird||Set Price Target||Buy||$95.00||N/A|
|10/19/2017||Stifel Nicolaus||Reiterated Rating||Hold||$89.00||N/A|
|9/21/2017||Morgan Stanley||Initiated Coverage||Equal -> Equal Weight||$88.00||Low|
|9/19/2017||Royal Bank Of Canada||Initiated Coverage||Sector Perform -> Sector Perform||$91.00||High|
|9/15/2017||Piper Jaffray Companies||Upgrade||Neutral -> Overweight||Low|
|8/29/2017||Credit Suisse Group||Reiterated Rating||Hold||$87.50||Low|
|8/7/2017||Northcoast Research||Upgrade||Neutral -> Buy||$109.00||High|
|5/10/2017||Barrington Research||Boost Price Target||Outperform -> Outperform||$98.00 -> $99.00||Low|
|4/11/2017||Craig Hallum||Initiated Coverage||Hold||Low|
|3/15/2017||Deutsche Bank AG||Initiated Coverage||Hold -> Hold||$87.00||Low|
|2/22/2017||Leerink Swann||Set Price Target||Hold||$91.50||N/A|
|2/21/2017||Evercore ISI||Boost Price Target||Hold||$80.00 -> $89.00||N/A|
|1/10/2017||Gabelli||Upgrade||Hold -> Buy||$104.00||N/A|
|11/3/2016||J P Morgan Chase & Co||Reiterated Rating||Hold||$81.50||N/A|
|10/11/2016||Goldman Sachs Group, Inc. (The)||Upgrade||Neutral -> Buy||$92.50||N/A|
|9/12/2016||Bank of America Corporation||Initiated Coverage||Buy||$92.50||N/A|
Earnings History for Henry Schein (NASDAQ:HSIC)Earnings History by Quarter for Henry Schein (NASDAQ HSIC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2017||Q2 17||$0.87||$0.88||$3.05 billion||$3.06 billion||View||Listen|
|5/9/2017||Q1 17||$0.83||$0.88||$2.83 billion||$2.92 billion||View||Listen|
|2/21/2017||Q416||$0.93||$0.94||$3.08 billion||$3.12 billion||View||Listen|
|11/2/2016||Q316||$0.83||$0.84||$2.88 billion||$2.87 billion||View||N/A|
|8/4/2016||Q216||$0.82||$0.82||$2.85 billion||$2.87 billion||View||N/A|
|5/3/2016||Q116||$0.70||$0.71||$2.66 billion||$2.70 billion||View||Listen|
|2/10/2016||Q415||$0.83||$0.84||$2.82 billion||$2.90 billion||View||Listen|
|11/4/2015||Q315||$0.74||$0.78||$2.70 billion||$2.70 billion||View||Listen|
|7/29/2015||Q215||$0.73||$0.73||$2.68 billion||$2.60 billion||View||Listen|
|5/4/2015||Q1||$0.64||$0.64||$2.54 billion||$25.00 billion||View||Listen|
|2/11/2015||Q414||$0.76||$0.78||$2.72 billion||$2.70 billion||View||Listen|
|11/6/2014||Q314||$0.66||$0.67||$2.55 billion||$2.62 billion||View||Listen|
|8/4/2014||Q214||$0.67||$0.68||$2.56 billion||$2.60 billion||View||Listen|
|5/6/2014||Q1||$0.57||$0.59||$2.43 billion||$2.40 billion||View||Listen|
|2/11/2014||Q413||$0.70||$0.72||$2.53 billion||$2.50 billion||View||Listen|
|11/5/2013||Q313||$0.61||$0.61||$2.37 billion||$2.30 billion||View||Listen|
|8/6/2013||Q2 2013||$0.62||$0.62||$2.39 billion||$2.40 billion||View||Listen|
|5/7/2013||Q1 2013||$0.54||$0.53||$2.25 billion||$2.30 billion||View||Listen|
|2/13/2013||Q4 2012||$0.61||$0.63||$2.40 billion||$2.40 billion||View||Listen|
|11/7/2012||Q312||$0.54||$0.54||$2.24 billion||$2.23 billion||View||N/A|
Earnings Estimates for Henry Schein (NASDAQ:HSIC)
2017 EPS Consensus Estimate: $6.78
2018 EPS Consensus Estimate: $6.34
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Henry Schein (NASDAQ:HSIC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Henry Schein (NASDAQ:HSIC)
Insider Ownership Percentage: 1.19%Insider Trades by Quarter for Henry Schein (NASDAQ:HSIC)
Institutional Ownership Percentage: 45.90%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/6/2017||Paul Rose||SVP||Sell||2,126||$172.51||$366,756.26|| |
|5/11/2017||Gerald A Benjamin||EVP||Sell||12,578||$175.10||$2,202,407.80|| |
|3/23/2017||Lorelei Mcglynn||SVP||Sell||9,300||$171.76||$1,597,368.00|| |
|3/20/2017||Michael Racioppi||SVP||Sell||9,969||$171.69||$1,711,577.61|| |
|3/17/2017||Mark E Mlotek||EVP||Sell||5,559||$170.98||$950,477.82|| |
|3/8/2017||James A Harding||SVP||Sell||10,552||$171.60||$1,810,723.20|| |
|3/8/2017||Philip A Laskawy||Director||Sell||1,103||$171.51||$189,175.53|| |
|3/2/2017||Michael S Ettinger||SVP||Sell||6,960||$171.09||$1,190,786.40|| |
|2/27/2017||Donald J Kabat||Director||Sell||4,334||$173.62||$752,469.08|| |
|2/22/2017||Paul Rose||SVP||Sell||6,821||$173.24||$1,181,670.04|| |
|2/22/2017||Steven Paladino||CFO||Sell||13,072||$173.40||$2,266,684.80|| |
|12/12/2016||Kurt P Kuehn||Director||Buy||1,000||$151.41||$151,410.00|| |
|11/3/2016||Mark E Mlotek||EVP||Sell||2,417||$155.19||$375,094.23|| |
|8/29/2016||Paul Brons||Director||Sell||3,381||$164.03||$554,585.43|| |
|6/2/2016||Gerald A Benjamin||EVP||Sell||9,991||$175.08||$1,749,224.28|| |
|5/16/2016||James A Harding||SVP||Sell||10,302||$172.60||$1,778,125.20|| |
|5/12/2016||Peter M Mccarthy||Insider||Sell||1,158||$171.75||$198,886.50|| |
|3/15/2016||Lonnie Shoff||CEO||Sell||3,028||$168.29||$509,582.12|| |
|3/14/2016||David Mckinley||Insider||Sell||3,339||$167.92||$560,684.88|| |
|3/14/2016||Norman S Matthews||Director||Sell||5,335||$167.75||$894,946.25|| |
|3/10/2016||Donald J Kabat||Director||Sell||1,218||$168.38||$205,086.84|| |
|3/7/2016||Barry J Alperin||Director||Sell||1,635||$167.36||$273,633.60|| |
|3/7/2016||Michael S Ettinger||SVP||Sell||5,423||$168.13||$911,768.99|| |
|3/4/2016||Philip A Laskawy||Director||Sell||1,317||$166.88||$219,780.96|| |
|3/2/2016||Louis W Sullivan||Director||Sell||11,735||$168.59||$1,978,403.65|| |
|3/2/2016||Mark E Mlotek||EVP||Sell||4,982||$167.93||$836,627.26|| |
|2/26/2016||Barry J Alperin||Director||Sell||7,540||$167.96||$1,266,418.40|| |
|2/24/2016||Robert Minowitz||Insider||Sell||9,648||$165.48||$1,596,551.04|| |
|2/22/2016||Michael Racioppi||SVP||Sell||21,567||$166.74||$3,596,081.58|| |
|2/17/2016||Stanley Komaroff||Insider||Sell||8,000||$163.53||$1,308,240.00|| |
|2/16/2016||Norman S Matthews||Director||Sell||4,230||$160.05||$677,011.50|| |
|2/12/2016||Steven Paladino||CFO||Sell||11,727||$157.21||$1,843,601.67|| |
|2/11/2016||Donald J. Kabat||Director||Sell||6,637||$156.36||$1,037,761.32|| |
|12/17/2015||Michael Racioppi||SVP||Sell||9,901||$155.92||$1,543,763.92|| |
|12/10/2015||Stanley M. Bergman||CEO||Sell||61,800||$155.45||$9,606,810.00|| |
|11/9/2015||Paul Rose||SVP||Sell||3,638||$151.92||$552,684.96|| |
|11/5/2015||Mark E. Mlotek||EVP||Sell||2,952||$155.00||$457,560.00|| |
|11/5/2015||Stanley Komaroff||Insider||Sell||6,297||$154.89||$975,342.33|| |
|9/16/2015||Philip A Laskawy||Director||Sell||4,000||$136.20||$544,800.00|| |
|5/6/2015||Paul Brons||Director||Sell||3,801||$136.70||$519,596.70|| |
|3/19/2015||Michael S Ettinger||SVP||Sell||4,352||$139.75||$608,192.00|| |
|3/18/2015||James P Breslawski||CEO||Sell||12,811||$139.45||$1,786,493.95|| |
|3/17/2015||Leonard A David||SVP||Sell||3,935||$140.00||$550,900.00|| |
|3/16/2015||Paul Rose||SVP||Sell||3,264||$140.13||$457,384.32|| |
|3/13/2015||Norman S Matthews||Director||Sell||9,200||$136.07||$1,251,844.00|| |
|3/11/2015||Philip A Laskawy||Director||Sell||2,669||$136.60||$364,585.40|| |
|3/10/2015||Donald J Kabat||Director||Sell||2,002||$138.00||$276,276.00|| |
|3/5/2015||Barry J Alperin||Director||Sell||6,637||$140.64||$933,427.68|| |
|2/24/2015||Stanley Komaroff||Insider||Sell||8,000||$141.69||$1,133,520.00|| |
|2/12/2015||Donald J Kabat||Director||Sell||5,000||$142.68||$713,400.00|| |
|2/12/2015||Gerald A Benjamin||EVP||Sell||22,116||$142.71||$3,156,174.36|| |
|2/12/2015||Robert Minowitz||Insider||Sell||11,254||$142.63||$1,605,158.02|| |
|12/18/2014||Leonard A David||SVP||Sell||3,557||$135.34||$481,404.38|| |
|12/9/2014||Stanley M Bergman||CEO||Sell||69,600||$135.56||$9,434,976.00|| |
|12/8/2014||Stanley M Bergman||CEO||Sell||23,485||$136.34||$3,201,944.90|| |
|11/24/2014||Stanley Komaroff||Insider||Sell||13,757||$133.06||$1,830,506.42|| |
|11/7/2014||Lorelei Mcglynn||SVP||Sell||15,746||$129.03||$2,031,706.38|| |
|11/7/2014||Mark E Mlotek||EVP||Sell||6,262||$128.75||$806,232.50|| |
|9/2/2014||Philip A Laskawy||Director||Sell||15,438||$119.40||$1,843,297.20|| |
|8/29/2014||Louis W Sullivan||Director||Sell||17,262||$119.99||$2,071,267.38|| |
|6/9/2014||Barry J Alperin||Director||Sell||7,500||$120.39||$902,925.00|| |
|6/2/2014||Gerald A Benjamin||EVP||Sell||12,354||$119.50||$1,476,303.00|| |
|5/28/2014||Norman S Matthews||Director||Sell||6,637||$118.68||$787,679.16|| |
|5/19/2014||Donald Kabat||Director||Sell||5,000||$116.30||$581,500.00|| |
|5/15/2014||Paul Brons||Director||Sell||5,363||$113.77||$610,148.51|| |
|3/19/2014||Barry Alperin||Director||Sell||7,500||$119.18||$893,850.00|| |
|3/17/2014||Lonnie Shoff||CEO||Sell||3,722||$119.06||$443,141.32|| |
|3/12/2014||Michael Ettinger||SVP||Sell||3,537||$119.20||$421,610.40|| |
|3/11/2014||David Mckinley||Insider||Sell||2,387||$119.65||$285,604.55|| |
|3/11/2014||James Breslawski||CEO||Sell||72,642||$119.35||$8,669,822.70|| |
|3/11/2014||Paul Rose||SVP||Sell||3,783||$119.72||$452,900.76|| |
|3/10/2014||Robert Minowitz||Insider||Sell||11,553||$119.98||$1,386,128.94|| |
|3/4/2014||Donald Kabat||Director||Sell||5,000||$119.15||$595,750.00|| |
|2/28/2014||Michael Racioppi||SVP||Sell||18,614||$118.91||$2,213,390.74|| |
|2/26/2014||Stanley Komaroff||Insider||Sell||18,000||$119.36||$2,148,480.00|| |
|2/25/2014||Mark Mlotek||EVP||Sell||20,333||$119.16||$2,422,880.28|| |
|2/20/2014||Steven Paladino||CFO||Sell||28,757||$117.79||$3,387,287.03|| |
|2/12/2014||Philip Laskawy||Director||Sell||5,851||$114.91||$672,338.41|| |
|12/19/2013||Mark Mlotek||EVP||Sell||22,004||$111.97||$2,463,787.88|| |
|12/19/2013||Michael Racioppi||SVP||Sell||29,257||$111.97||$3,275,906.29|| |
|12/17/2013||Gerald Benjamin||EVP||Sell||41,664||$111.66||$4,652,202.24|| |
|12/17/2013||James Breslawski||CEO||Sell||57,754||$111.91||$6,463,250.14|| |
|12/16/2013||Steven Paladino||CFO||Sell||47,652||$112.31||$5,351,796.12|| |
|12/13/2013||Stanley Bergman||CEO||Sell||78,000||$111.90||$8,728,200.00|| |
|12/6/2013||Leonard David||SVP||Sell||13,968||$113.14||$1,580,339.52|| |
|11/26/2013||Stanley Komaroff||Insider||Sell||22,329||$114.79||$2,563,145.91|| |
|8/23/2013||Philip Laskawy||Director||Sell||21,637||$103.17||$2,232,289.29|| |
|8/22/2013||Norman Matthews||Director||Sell||9,851||$103.95||$1,024,011.45|| |
|8/20/2013||Louis Sullivan||Director||Sell||15,000||$103.91||$1,558,650.00|| |
|8/12/2013||Donald Kabat||Director||Sell||2,500||$106.25||$265,625.00|| |
|6/18/2013||Barry J Alperin||Director||Sell||7,500||$97.74||$733,050.00|| |
|5/8/2013||James A Harding||CTO||Sell||12,000||$92.64||$1,111,680.00|| |
|3/8/2013||Donald J Kabat||Director||Sell||4,038||$90.00||$363,420.00|| |
|12/4/2012||Donald J Kabat||Director||Sell||15,000||$80.04||$1,200,600.00|| |
Headline Trends for Henry Schein (NASDAQ:HSIC)
Latest Headlines for Henry Schein (NASDAQ:HSIC)
Loading headlines, please wait.
Henry Schein (HSIC) Chart for Tuesday, October, 24, 2017